How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Binge (Eating) Disorders Market
- By Treatment Type: Pharmacotherapy, Psychotherapy, Nutritional Counseling, Behavioral Therapy, Hospitalization
- By Patient Age Group: Adolescents, Adults, Elderly
- By Distribution Channel: Hospitals, Specialty Clinics, Outpatient Clinics, Online Platforms
- By End User: Patients, Healthcare Providers, Research Institutions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacotherapy leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Binge (Eating) Disorders Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Patient Age Group 3
Distribution Channel 4
End User 3
Companies profiled
Johnson & Johnson
Pfizer Inc.
Eli Lilly and Company
AbbVie Inc.
Otsuka Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited
H. Lundbeck A/S
Alkermes plc
Acadia Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc.
Neurocrine Biosciences Inc.
Indivior PLC
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Otsuka Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Takeda Pharmaceutical Company Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Alkermes plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Acadia Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sunovion Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Neurocrine Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Indivior PLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Mitsubishi Tanabe Pharma Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Jazz Pharmaceuticals plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Horizon Therapeutics plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,582M by 2033 · 4.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacotherapy32.9
- Psychotherapy12.6
- Nutritional Counseling21.8
- Behavioral Therapy14.0
- Hospitalization18.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,716M → $2,246M · 3.4%
Europe$1,196M → $1,952M · 6.3%
Asia Pacific$1,092M → $1,563M · 4.6%
Latin America$676.2M → $1,112M · 6.4%
Middle East and Africa$520.1M → $681.2M · 3.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.782026
4.782027
4.812028
4.802029
4.822030
4.842031
4.852032
4.852033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson21.8
- Pfizer Inc.17.3
- Eli Lilly and Company8.6
- AbbVie Inc.3.8
- Otsuka Pharmaceutical Co. Ltd.10.6
- Takeda Pharmaceutical Company Limited9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type31.5%
Patient Age Group16.0%
Distribution Channel24.7%
End User27.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.7
- Europe25.8
- Asia Pacific20.7
- Latin America14.7
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 93 | 97 | 86 | 91 | 88 | 87 | 90 |
| Pfizer Inc. | 93 | 88 | 92 | 78 | 82 | 84 | 86 |
| Eli Lilly and Company | 71 | 72 | 75 | 86 | 73 | 69 | 74 |
| AbbVie Inc. | 65 | 82 | 68 | 58 | 82 | 77 | 72 |
| Otsuka Pharmaceutical Co. Ltd. | 69 | 61 | 56 | 57 | 54 | 51 | 58 |
| Takeda Pharmaceutical Company Limited | 55 | 52 | 68 | 65 | 67 | 69 | 63 |
| H. Lundbeck A/S | 59 | 55 | 47 | 64 | 59 | 62 | 58 |
| Alkermes plc | 43 | 45 | 46 | 35 | 38 | 36 | 41 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- Pfizer Inc.
- Eli Lilly and Company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Pfizer Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Eli Lilly and Company | ◐ | ◐ | ✓ | ◐ | − | ◐ |
| AbbVie Inc. | ◐ | ✓ | ◐ | − | ◐ | ◐ |
| Otsuka Pharmaceutical Co. Ltd. | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Takeda Pharmaceutical Company Limited | − | − | − | ◐ | − | − |
| H. Lundbeck A/S | − | − | ◐ | ✓ | ◐ | ✓ |
| Alkermes plc | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson90
2Pfizer Inc.86
3Eli Lilly and Company74
4AbbVie Inc.72
5Takeda Pharmaceutical Company Limited63
6Otsuka Pharmaceutical Co. Ltd.58
7H. Lundbeck A/S58
8Alkermes plc41
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Johnson & JohnsonPfizer Inc.
Challenger2
Strong scale, closing on the leaders.
Eli Lilly and CompanyAbbVie Inc.
Contender3
Focused players with pockets of strength.
Otsuka Pharmaceutical Co. Ltd.Takeda Pharmaceutical Company LimitedH. Lundbeck A/S
Niche1
Specialists in a single segment or region.
Alkermes plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Binge (Eating) Disorders Market — a $185M beachhead inside a $2.78B market.
Beachhead (SOM)$185Mobtainable near-term
Serviceable (SAM)$1.05Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Pharmacotherapy
Best fit — highest urgency & budget in Treatment Type.
Economic buyer78 fit
Psychotherapy
Strong fit — clear ROI and a fast path to value.
End user70 fit
Nutritional Counseling
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Patient Age Group & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve23%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Binge (Eating) Disorders Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation13%
Closed-won6%
$16.9KCAC
$68KLTV
4.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Binge (Eating) Disorders Market is a high-growth opportunity — $10.4B by 2033, compounding at 10.6%.
TAM · 2025$4.62Btoday
TAM · 2033$10.4Bforecast
CAGR10.6%2027–2033
Cumulative$64.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.4BTotal addressable market
SAM$3.72BServiceable available market
SOM$813MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.6% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.4BLarge & growingTAM by 2033 at 10.6% CAGR
$3.72BServiceable nowreachable with today’s model
$813MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.10BBear6.9% CAGR
$10.4BBase10.6% CAGR
$13.3BBull14.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Patient Age Group optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Binge (Eating) Disorders Market — a $4.44B market by 2033. Plan: grow share from 10.9% to 18.7%.
Market size · 2033$4.44Btotal addressable
Market CAGR11.0%2027–2033
Target share18.7%from 10.9% today
Revenue ambition$830Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.9% | 18.7% | At risk |
| Revenue | $436M | $830M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 33.6% | 38.2% | Behind |
| Customer retention | 89.0% | 95.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Patient Age Group capability
A defensible second engine — invest in Patient Age Group to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Patient Age Group
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $98M capacity & capability investment
- Greenlight bolt-on M&A in Patient Age Group
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Binge (Eating) Disorders Market conversation — a $6.12B market you can size, segment and defend in minutes.
Market size · 2033$6.12Btotal opportunity
Growth3.4%CAGR to 2033
Addressable buyers945+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 4 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Johnson & JohnsonPfizer Inc.Eli Lilly and CompanyAbbVie Inc.Otsuka Pharmaceutical Co. Ltd.Takeda Pharmaceutical Company LimitedH. Lundbeck A/SAlkermes plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Binge (Eating) Disorders Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Binge (Eating) Disorders Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Binge Eating Disorder Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportBinocular AR Glasses Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportBinocular Camera Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBinocular Loupe Market
Market size, share, segmentation and regional forecast.
$305M market · 2025 base year
View reportBinocular Magnifiers Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBinocular Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBinocular Microscope Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportBinocular Stereo Vision Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportBinocular Telescope Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBinoculars And Telescopes Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBio Based Lubricant Market
Market size, share, segmentation and regional forecast.
$309M market · 2025 base year
View reportBio Based Synthetic Leather Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.